REFERENCES
- UNAIDS WHO.. Report on the Global HIV/AIDS Epidemic. Geneva, WHO. 2002
- A., Sabin. Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal entry. Proc. Natl. Acad. Sci. USA. 89: 8852–8856, 1992, [CSA]
- A., Sabin. HIV vaccination dilemma. Nature. 362: 212, 1993, [CROSSREF]
- L., Corey. HIV vaccine development. Topics HIV Med.. 8(6)1–16, 2000
- F. R., Steel. Gp120 good, bad or indifferent?. Nature Med.. 1: 1105–1109, 1995, [CSA], [CROSSREF]
- Lower sights for AIDS vaccine, experts say, Science Headlines, Reuters, 30, January. 2000
- S. H., Pincus, K. G., Messer, D. H., Schwartz, G. K., Lewis, B. S., Graham, W. A., Blattner, G., Fisher. Differences in the antibody response to human immunodeficency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J. Clin. Invest.. 91: 1987–1996, 1993, [CSA]
- S. H., Pincus, K. G., Messer, P. L., Nara, W. A., Blattner, G., Colclough, M., Reitz. Temporal analysis of the antibody response to HIV envelope protein in HIV- infected laboratory workers. J. Clin. Invest.. 93: 2505–2513, 1994
- S. H., Pincus, K. G., Messer, R., Cole, R., Ireland, T. C., VanCott, A., Pinter, D. H., Schwartz, B. S., Graham, G. J., Gorse. et al.. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol.. 158: 3511–3520, 1997
- G., Pialoux, J. L., Excler, Y., Riviere, G., Gonzalez-Canali, V., Feuillie, P., Coulaud, J. C., Gluckman, T. J., Matthews, B., Meignier, M. P., Kieny. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retrovir.. 11: 373–381, 1995, [CSA]
- P. W., Berman, T. J., Matthews, L., Riddle, M., Champe, M. R., Hobbs, G. R., Nakamura, J., Mercer, D. J., Eastman, C., Lucas, A. J., Langlois. Neutralization of multiple laboratory and clinical isolates of human immunodeficency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol.. 66: 4464–4469, 1992, [CSA]
- J. R., Mascola, S. W., Snyder, O. S., Weislow, S. M., Belay, R. B., Belshe, D. H., Schwartz, M. L., Clements, R., Dolin, B. S., Graham, G. J., Gorse, M. C., Keefer, M. J., McElrath, M. C., Walker, K. F., Wagner, J. G., McNeil, F. E., McCutchan, D. S., Burke. Immunization with envelope subunit vaccine products elicites neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis.. 173: 340–348, 1996
- E., Coeffier, J. L., Excler, M. P., Kieny, B., Meignier, C., Moste, J., Tartaglia, G., Pialoux, D., Salmon-Ceron, C., Leclerc. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. AIDS Res. Hum. Retrovir.. 13: 1471–1485, 1997, [CSA]
- M. J., McElrath, L., Corey, P. D., Greenberg, T. J., Matthews, D. C., Montefiori, L., Rowen, L., Hood, J. I., Mullins. Human immuneficiency infection despite prior vaccination with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA. 93: 3972–3977, 1996, [CSA], [CROSSREF]
- R. I., Connor, B. T., Korber, B. S., Graham, B. H., Hahn, D. D., Ho, B. D., Walker, A. U., Neumann, S. H., Vermund, J., Mestecky, S., Jackson, E., Fenamore, Y., Cao, F., Gao, S., Kalams, K. J., Kunstman, D., McDonald, N., McWilliams, A., Trkola, J. P., Moore, S. M., Wolinsky. Immunological and virological analysis of persons infected by human immunodeficency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol.. 72: 1552–1576, 1998, [CSA]
- J. A., Levy. What can be achieved with an HIV vaccine?. Lancet. 357: 223–224, 2001, [CROSSREF]
- D. F., Gordon. National Intelligence Council, The next wave of HIV/AIDS: Nigeria, Ethiopia, Russia, India, and China. Report of National Intelligence Council ICA 2002–04D, September. 2002